Arcturus Therapeutics Director Moncef Slaoui Receives 15,000 Stock Options

This Form 4 filing reports that Moncef Slaoui, a director of Arcturus Therapeutics Holdings Inc. (ARCT), received a grant of 15,000 stock options on June 5, 2026. The options have an exercise price of $7.30 per share and expire on June 5, 2036. The shares underlying the option vest monthly over a one-year period from the date of grant. This represents the 2026 annual grant to the reporting person as a member of the Board of Directors. The transaction was reported on June 15, 2026, and was signed by Grant Levine as attorney-in-fact. Following this transaction, the director now holds 15,000 stock options that can be converted into common stock of Arcturus Therapeutics.